Skip to content

Riding the Wave | Differentiating Bispecifics and CAR-T for Relapsed Refractory Multiple Myeloma
Expert Consult #1: Selecting BCMA- and GPRC5D-Directed Therapies
*Pre-assessment*

Before you view this Expert Consult video, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit. 

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.
1.What are your credentials?(Required.)
2.What is your community of practice?
3.Which of the following therapies has demonstrated the longest median progression-free survival in phase 1 studies of patients with relapsed/refractory multiple myeloma?(Required.)
4.Enrollment of patients with which of the following characteristics is a key difference in the study populations presented in the MonumenTAL-1 (talquetamab) study compared with the MagnetisMM-3, MajesTEC-1, KarMMa-1 or CARTITUDE-1 studies? 
5.An organizational task force is developing monitoring plans for patients receiving bispecific antibodies for relapsed/refractory multiple myeloma. Monitoring for which of the following adverse effects should be included in monitoring plans for talquetamab but not for elranatamab or teclistamab? 
6.A 68-year-old male was referred for management of relapsed/refractory multiple myeloma after 7 prior therapies including 2 proteasome inhibitors, 2 immunomodulatory agents, and 2 anti-CD38 monoclonal antibodies. After reviewing treatment options with him, he asks which of the following severe (grade 3 or higher) adverse effects is more likely to occur if he chooses a BCMA-directed bispecific antibody rather than a BCMA-directed CAR-T? Which of the following is the best response? 
7.A 63-year-old female diagnosed with IgG multiple myeloma with deletion 17p presents for a treatment consult. She received 5 prior therapies including 2 proteasome inhibitors, 2 immunomodulatory agents, and 2 anti-CD38 monoclonal antibodies. She is the caregiver for her spouse with advanced Alzheimer’s disease. They live 200 miles from a cellular therapy center. She wishes to receive treatment close to home. Which therapy is best for her at this time? 
8.Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity) 

Completing the fields below does not immediately qualify you for a CME certificate. Only after completing the post-survey & evaluation form will a certificate be issued.

*Please note that we will not forward or sell your contact information.
Privacy & Cookie Notice